Leavitt v. Ethicon, Inc.

District Court, D. Vermont·Decided August 19, 2021·No. 2:20-cv-00176·Unknown

Opinion

UNITED STATES DISTRICT COURT meee FOR THE 2821 AUG 19 AMII: □□ DISTRICT OF VERMONT CLERK JACINTA LEAVITT and PAUL LEAVITT, _ ) ex Plaintiffs, V. Case No. 2:20-cv-00176 ETHICON, INC., and JOHNSON & JOHNSON, ) Defendants. OPINION AND ORDER GRANTING DEFENDANTS’ MOTION TO LIMIT EXPERT TESTIMONY AND GRANTING PLAINTIFFS’ MOTION TO LIMIT EXPERT TESTIMONY (Docs. 30 & 32) This case arises out of alleged injuries suffered by Plaintiff Jacinta Leavitt (“Plaintiff J. Leavitt”) following the implantation of tension-free vaginal tape (“TVT’”) for the treatment of her stress urinary incontinence. Plaintiff Paul Leavitt (“Plaintiff P. Leavitt”) is Plaintiff J. Leavitt’s husband. Plaintiffs assert negligence, strict liability for failure to warn, strict liability for design defect, negligent infliction of emotional distress, gross negligence, loss of consortium, and punitive damages claims against Defendants. Pending before the court is Defendants’ motion to exclude certain opinions and testimony of Plaintiffs’ expert witness Donald Ostergard, MD, (Doc. 30), and Plaintiffs’ motion to exclude certain opinions and testimony of Defendants’ expert witness Lawrence Lind, MD. (Doc. 32.) Oral argument was held on June 9, 2021, after which the court took the pending motions under advisement. With regard to Dr. Ostergard, in the course of oral argument, the court ruled on the record that provided Dr. Ostergard testifies about the foundation for his opinions, he is qualified to testify that the TVT caused Plaintiff J. Leavitt’s dyspareunia and pelvic floor muscle tenderness and spasm.

Plaintiffs are represented by D. Michael Noonan, Esq., Kenneth J. Brennan, Esq., Maxwell S. Kennerly, Esq., Steven D. Davis, Esq., and Tyler J. Schneider, Esq. Defendants are represented by James M. Campbell, Esq., and Kathleen M. Guilfoyle, Esq. 1. Conclusions of Law and Analysis. A. Standard of Review. Under Federal Rule of Evidence 702: A witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify in the form of an opinion or otherwise if: (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliably applied the principles and methods to the facts of the case. The district court functions as the gatekeeper for expert testimony, ensuring “‘that an expert’s testimony both rests on a reliable foundation and is relevant to the task at hand.’” Amorgianos v. Nat’l R.R. Passenger Corp., 303 F.3d 256, 265 (2d Cir. 2002) (citing Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 597 (1993)). In determining the reliability of expert testimony, the court engages in “a preliminary assessment of whether the reasoning or methodology underlying the testimony is scientifically valid and of whether that reasoning or methodology properly can be applied to the facts in issue.” Daubert, 509 U.S. at 592-93. Under Daubert and its progeny, relevant factors include the theory’s verifiability, the extent to which it “has been subjected to peer review and publication[,]” the extent to which a technique is subject to “standards controlling the technique’s operation,” the “known or potential rate of error,” and the “degree of acceptance” within the relevant scientific community.” Jd. at 593-94. “[T]he test of reliability is ‘flexible,’ and Daubert’s list of specific factors neither necessarily nor exclusively applies to all experts or in every case.” Restivo v. Hessemann,

846 F.3d 547, 576 (2d Cir. 2017), cert. denied, 138 S. Ct. 644 (2018) (quoting Kumho Tire Co. v. Carmichael, 526 U.S. 137, 141 (1999)). “[W |hen an expert opinion is based on data, a methodology, or studies that are simply inadequate to support the conclusions reached, Daubert and Rule 702 mandate the exclusion of that unreliable opinion testimony.” Amorgianos, 303 F.3d at 266. The court has the same “broad latitude when it decides how to determine reliability as it enjoys in respect to its ultimate reliability determination.” Kumho Tire Co., 526 U.S. at 142 (emphasis in original); see also Restivo, 846 F.3d at 575 (““Thus, in analyzing the admissibility of expert evidence, the district court has broad discretion in determining what method is appropriate for evaluating reliability under the circumstances of each case.”) (internal quotation marks omitted). Admissible testimony under Rule 702 may still be excluded under Federal Rule of Evidence 403, when its “probative value is substantially outweighed by [the] danger of ... unfair prejudice, confusing the issues, misleading the jury, undue delay, wasting time, or needlessly presenting cumulative evidence.” Fed. R. Evid. 403. “Expert evidence can be both powerful and quite misleading because of the difficulty in evaluating it. Because of this risk, the judge in weighing possible prejudice against probative force under Rule 403 of the present rules exercises more control over experts than over lay witnesses.” Daubert, 509 U.S. at 595 (internal quotation marks omitted). B. Whether to Grant Defendants’ Motion to Limit Opinions of Dr. Ostergard. Defendants assert that the following case-specific opinions of Donald Ostergard, MD, should be excluded because they are unreliable, irrelevant, unhelpful, and otherwise inadmissible: (1) opinions regarding complications not experienced by Plaintiff J. Leavitt; (2) opinions concerning the cause of Plaintiff J. Leavitt’s alleged injuries; and (3) opinions regarding safer alternative designs, treatments, and procedures. !

' At the hearing on the motion, the parties agreed that Dr. Ostergard would not opine that Defendants’ product was defective, would not discuss informed consent, and would not testify about the Instructions for Use.

1. Opinions and Testimony Regarding Complications Not Experienced by Plaintiff J. Leavitt. In the section of his report labeled “Future Possible Adverse Events[,]” Dr. Ostergard opines, to a reasonable degree of medical probability, that “[s]ince most of the implanted Ethicon [] TVT pubourethral sling mesh remains in the dense fibrotic tissue produced by the device in [Plaintiff J.] Leavitt’s body, the potential exists for . . . cancer associated with the mesh and infection for as long as the mesh remains in her body[.]” (Doc. 30-1 at 20-21, § 81.) Defendants argue that Dr. Ostergard’s opinion that complete removal of the TVT is “not possible due to the degradation of the polypropylene which weakens the mesh to the point that it literally falls apart[,]” id. at 5, as well as his testimony regarding the possibility that Plaintiff J. Leavitt may develop cancer or an infection as a result of complications from her residual TVT, should be excluded because the TVT has been removed and no longer poses a risk” and, even if it does, any remaining risk is speculative. Plaintiffs counter that Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Leavitt v. Ethicon, Inc., (D. Vt. 2021).

Leavitt v. Ethicon, Inc. (Leavitt v. Ethicon, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Eleanor M. Stagl v. Delta Air Lines, Inc.
117 F.3d 76 (Second Circuit, 1997)
In Re Zyprexa Products Liability Litigation
489 F. Supp. 2d 230 (E.D. New York, 2007)
Highland Capital Management, L.P. v. Schneider
379 F. Supp. 2d 461 (S.D. New York, 2005)
Carol Marmo v. Tyson Fresh Meats
457 F.3d 748 (Eighth Circuit, 2006)
Tyree v. Boston Scientific Corp.
54 F. Supp. 3d 501 (S.D. West Virginia, 2014)
Mullins v. Johnson & Johnson
236 F. Supp. 3d 940 (S.D. West Virginia, 2017)
Tardif v. City of N.Y.
344 F. Supp. 3d 579 (S.D. Illinois, 2018)
Restivo v. Hessemann
846 F.3d 547 (Second Circuit, 2017)
Davids v. Novartis Pharmaceuticals Corp.
857 F. Supp. 2d 267 (E.D. New York, 2012)
Rotman v. Progressive Insurance
955 F. Supp. 2d 272 (D. Vermont, 2013)
Touchet v. Estis Well Serv., L.L.C.
138 S. Ct. 644 (Supreme Court, 2018)